These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 21562035

  • 1. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC, Mir SE, Noske D, Van Noorden CJ, Würdinger T.
    Clin Cancer Res; 2011 Jul 01; 17(13):4200-7. PubMed ID: 21562035
    [Abstract] [Full Text] [Related]

  • 2. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A, Oza A.
    Drug News Perspect; 2010 Sep 01; 23(7):425-9. PubMed ID: 20862394
    [Abstract] [Full Text] [Related]

  • 3. Targeting WEE1 Kinase in Cancer.
    Matheson CJ, Backos DS, Reigan P.
    Trends Pharmacol Sci; 2016 Oct 01; 37(10):872-881. PubMed ID: 27427153
    [Abstract] [Full Text] [Related]

  • 4. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J, Würdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, Kaspers GJ.
    BMC Cancer; 2011 Apr 29; 11():156. PubMed ID: 21529352
    [Abstract] [Full Text] [Related]

  • 5. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
    Krajewska M, Heijink AM, Bisselink YJ, Seinstra RI, Silljé HH, de Vries EG, van Vugt MA.
    Oncogene; 2013 Jun 13; 32(24):3001-8. PubMed ID: 22797065
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. WEE1 inhibition and genomic instability in cancer.
    Vriend LE, De Witt Hamer PC, Van Noorden CJ, Würdinger T.
    Biochim Biophys Acta; 2013 Dec 13; 1836(2):227-35. PubMed ID: 23727417
    [Abstract] [Full Text] [Related]

  • 9. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
    Esposito F, Giuffrida R, Raciti G, Puglisi C, Forte S.
    Int J Mol Sci; 2021 Oct 01; 22(19):. PubMed ID: 34639030
    [Abstract] [Full Text] [Related]

  • 10. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H, Iwasawa Y, Okada M, Arai T, Nishibata T, Kobayashi M, Kimura T, Kaneko N, Ohtani J, Yamanaka K, Itadani H, Takahashi-Suzuki I, Fukasawa K, Oki H, Nambu T, Jiang J, Sakai T, Arakawa H, Sakamoto T, Sagara T, Yoshizumi T, Mizuarai S, Kotani H.
    Mol Cancer Ther; 2009 Nov 01; 8(11):2992-3000. PubMed ID: 19887545
    [Abstract] [Full Text] [Related]

  • 11. Wee1 kinase as a target for cancer therapy.
    Do K, Doroshow JH, Kummar S.
    Cell Cycle; 2013 Oct 01; 12(19):3159-64. PubMed ID: 24013427
    [Abstract] [Full Text] [Related]

  • 12. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
    Knight GL, Turnell AS, Roberts S.
    J Virol; 2006 Aug 01; 80(15):7416-26. PubMed ID: 16840322
    [Abstract] [Full Text] [Related]

  • 13. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L, Chilà R, Lupi M, Ricci F, Celenza C, Mazzoletti M, Broggini M, Damia G.
    Cell Cycle; 2012 Jul 01; 11(13):2507-17. PubMed ID: 22713237
    [Abstract] [Full Text] [Related]

  • 14. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, Peter Vandertop W, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJ, Würdinger T.
    Cancer Cell; 2010 Sep 14; 18(3):244-57. PubMed ID: 20832752
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M, Sharpe R, Garcia-Murillas I, Gevensleben H, Hurd MS, Shumway SD, Toniatti C, Ashworth A, Turner NC.
    Cancer Discov; 2012 Jun 14; 2(6):524-39. PubMed ID: 22628408
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J, Fang H, Yang F, Ji W, Guan N, Sun Z, Shi Y, Zhou G, Guan X.
    Neoplasia; 2018 May 14; 20(5):478-488. PubMed ID: 29605721
    [Abstract] [Full Text] [Related]

  • 19. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S, Zabludoff S.
    Clin Cancer Res; 2008 Jul 01; 14(13):4032-7. PubMed ID: 18593978
    [Abstract] [Full Text] [Related]

  • 20. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD, Li J, Liu Y, Hurd MS, Schuller AG, Long B, Hirsch HA, Feldman I, Benita Y, Toniatti C, Zawel L, Fawell SE, Gilliland DG, Shumway SD.
    Mol Cancer Ther; 2013 Aug 01; 12(8):1442-52. PubMed ID: 23699655
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.